Archives By Month: July 2018

Results from Phase 1b Studies for C3 Inhibitor

Posted on July 12, 2018

This is the sub cutaneous daily injection which inhibits the C3 part of the complement system (rather than C5) and is promising for those who still need blood transfusions whilst […]

Phase 1 Trial starts for Achillion’s Oral Therapy

Posted on July 12, 2018

“Achillion Pharmaceuticals, Inc. announced (10 July) that the Company had begun dosing healthy volunteer subjects in a first-in-human phase 1 trial of ACH-5548, an oral small-molecule complement factor D inhibitor. ACH-5548 […]